HERES trial: Trastuzumab and standard treatment with chemo- and immunotherapy as first-line treatment for HER2positive esophageal squamous cell carcinoma patients

K. Egebjerg; L. Baeksgaard; R. Garbyal; P. Pfeiffer; T. Caterino; J. K. Bjerregaard; M. N. Yilmaz; A. Wanders; L. B. J. Thorsen; S. Hamilton Dutoit; L. Ahlborn; N. Pallisgaard; P. M. Mau-Sorensen

doi:10.1016/j.annonc.2024.05.404

HERES trial: Trastuzumab and standard treatment with chemo- and immunotherapy as first-line treatment for HER2positive esophageal squamous cell carcinoma patients

K. Egebjerg
, L. Baeksgaard
, R. Garbyal
, P. Pfeiffer
, T. Caterino
, J. K. Bjerregaard
, M. N. Yilmaz
, A. Wanders
, L. B. J. Thorsen
, S. Hamilton Dutoit
, L. Ahlborn
, N. Pallisgaard
, P. M. Mau-Sorensen

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning

Originalsprog	Engelsk
Artikelnummer	492TiP
Tidsskrift	Annals of Oncology
Vol/bind	35
Udgave nummer	Suppl. 1
Sider (fra-til)	S195-S196
Antal sider	2
ISSN	0923-7534
DOI	https://doi.org/10.1016/j.annonc.2024.05.404
Status	Udgivet - jun. 2024
Begivenhed	ESMO Gastrointestinal Cancers Congress 2024 - Munich, Tyskland Varighed: 26 jun. 2024 → 29 jun. 2024 https://www.esmo.org/meeting-calendar/past-meetings/esmo-gastrointestinal-cancers-congress-2024

Konference

Konference	ESMO Gastrointestinal Cancers Congress 2024
Land/Område	Tyskland
By	Munich
Periode	26/06/2024 → 29/06/2024
Internetadresse	https://www.esmo.org/meeting-calendar/past-meetings/esmo-gastrointestinal-cancers-congress-2024

Bibliografisk note

Abstrakt No. 492TiP

Adgang til dokumentet

10.1016/j.annonc.2024.05.404

AUB Link

Søg efter materialet i Aalborg Universitetsbiblioteks søgemaskine

Citationsformater

Egebjerg, K., Baeksgaard, L., Garbyal, R., Pfeiffer, P., Caterino, T., Bjerregaard, J. K., Yilmaz, M. N., Wanders, A., Thorsen, L. B. J., Dutoit, S. H., Ahlborn, L., Pallisgaard, N., & Mau-Sorensen, P. M. (2024). HERES trial: Trastuzumab and standard treatment with chemo- and immunotherapy as first-line treatment for HER2positive esophageal squamous cell carcinoma patients. Annals of Oncology, 35(Suppl. 1), S195-S196. Artikel 492TiP. https://doi.org/10.1016/j.annonc.2024.05.404

@article{57a7d517c77e4376abee0f9d415486b1,

title = "HERES trial: Trastuzumab and standard treatment with chemo- and immunotherapy as first-line treatment for HER2positive esophageal squamous cell carcinoma patients",

author = "K. Egebjerg and L. Baeksgaard and R. Garbyal and P. Pfeiffer and T. Caterino and Bjerregaard, \{J. K.\} and Yilmaz, \{M. N.\} and A. Wanders and Thorsen, \{L. B. J.\} and Dutoit, \{S. Hamilton\} and L. Ahlborn and N. Pallisgaard and Mau-Sorensen, \{P. M.\}",

note = "Abstract No. 492TiP; ESMO Gastrointestinal Cancers Congress 2024 ; Conference date: 26-06-2024 Through 29-06-2024",

year = "2024",

month = jun,

doi = "10.1016/j.annonc.2024.05.404",

language = "English",

volume = "35",

pages = "S195--S196",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier",

number = "Suppl. 1",

url = "https://www.esmo.org/meeting-calendar/past-meetings/esmo-gastrointestinal-cancers-congress-2024",

}

Egebjerg, K, Baeksgaard, L, Garbyal, R, Pfeiffer, P, Caterino, T, Bjerregaard, JK, Yilmaz, MN, Wanders, A, Thorsen, LBJ, Dutoit, SH, Ahlborn, L, Pallisgaard, N & Mau-Sorensen, PM 2024, 'HERES trial: Trastuzumab and standard treatment with chemo- and immunotherapy as first-line treatment for HER2positive esophageal squamous cell carcinoma patients', Annals of Oncology, bind 35, nr. Suppl. 1, 492TiP, s. S195-S196. https://doi.org/10.1016/j.annonc.2024.05.404

HERES trial: Trastuzumab and standard treatment with chemo- and immunotherapy as first-line treatment for HER2positive esophageal squamous cell carcinoma patients. / Egebjerg, K.; Baeksgaard, L.; Garbyal, R. et al.
I: Annals of Oncology, Bind 35, Nr. Suppl. 1, 492TiP, 06.2024, s. S195-S196.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning

TY - ABST

T1 - HERES trial: Trastuzumab and standard treatment with chemo- and immunotherapy as first-line treatment for HER2positive esophageal squamous cell carcinoma patients

AU - Egebjerg, K.

AU - Baeksgaard, L.

AU - Garbyal, R.

AU - Pfeiffer, P.

AU - Caterino, T.

AU - Bjerregaard, J. K.

AU - Yilmaz, M. N.

AU - Wanders, A.

AU - Thorsen, L. B. J.

AU - Dutoit, S. Hamilton

AU - Ahlborn, L.

AU - Pallisgaard, N.

AU - Mau-Sorensen, P. M.

N1 - Abstract No. 492TiP

PY - 2024/6

Y1 - 2024/6

U2 - 10.1016/j.annonc.2024.05.404

DO - 10.1016/j.annonc.2024.05.404

M3 - Conference abstract in journal

SN - 0923-7534

VL - 35

SP - S195-S196

JO - Annals of Oncology

JF - Annals of Oncology

IS - Suppl. 1

M1 - 492TiP

T2 - ESMO Gastrointestinal Cancers Congress 2024

Y2 - 26 June 2024 through 29 June 2024

ER -